Anxiety, Depression & Mood — FAQs

Talk to Dr. Samuel directly — your first 20 minutes are free.

Most people who reach out here don’t feel ready to talk on the phone. Start whichever way feels safest.

Text me what’s going on

The message is already written — just press send. I reply personally: usually within a few hours, always within 24.

Or have me call you — you pick the time →

No forms, no gatekeepers, no obligation. English or فارسی.

Call for a Free 20-Minute Consult — 6047210604

Anxiety — what it is, symptoms, and causes

1. What is anxiety and how is it different from normal worry?

Anxiety is the body and mind’s natural response to perceived threat — a future-oriented state involving apprehension, physiological arousal, and avoidance preparation [1]. Normal worry is brief, proportionate to a real stressor, and resolves when the situation does. An anxiety disorder is diagnosed when worry or fear is excessive, persistent (typically ≥6 months for generalized anxiety disorder), out of proportion to actual risk, hard to control, and significantly impairs daily functioning [2]. Large population surveys suggest that up to 33.7% of people are affected by an anxiety disorder during their lifetime [151].

2. What are the symptoms of an anxiety disorder?

Core symptoms include excessive worry that is difficult to control, restlessness or feeling on edge, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance — at least three of these are required for generalized anxiety disorder [2]. Cognitive symptoms include catastrophic thinking, anticipatory dread, and difficulty tolerating uncertainty [5].

3. What does a panic attack feel like and how long does it last?

A panic attack is an abrupt surge of intense fear or discomfort that peaks within about 10 minutes and typically lasts 20–30 minutes total, with at least four of the following: pounding heart, sweating, trembling, shortness of breath, choking sensation, chest pain, nausea, dizziness, chills or hot flushes, numbness/tingling, derealization, fear of losing control, or fear of dying [2,6]. Although extremely distressing, panic attacks are not physically dangerous and do not cause heart attacks in healthy individuals [7]. In a U.S. national survey, 22.7% of adults reported isolated panic attacks (without panic disorder or agoraphobia) at some point in their lives, and 3.7% had panic disorder without agoraphobia [152].

4. What is the difference between a panic attack and an anxiety attack?

“Panic attack” is a clinical DSM-5 term with specific diagnostic criteria: an abrupt surge of intense fear that peaks within minutes and includes at least four physiological symptoms [2]. “Anxiety attack” is a colloquial term not in the DSM — it usually describes a more gradual buildup of worry, tension, and physical symptoms in response to an identifiable stressor, typically lasting longer at lower intensity [6]. Panic attacks are typically unexpected and decoupled from triggers, whereas anxiety symptoms tend to be tied to specific stressors and accumulate over time [9].

5. What causes anxiety disorders?

Twin-study meta-analysis estimates heritability at about 43% for panic disorder and 32% for generalized anxiety disorder [153].

6. Is anxiety genetic or hereditary?

Yes, in part. Twin-study meta-analysis estimates heritability at about 43% for panic disorder and 32% for generalized anxiety disorder [153]. Genome-wide association studies have identified multiple genetic loci linked to anxiety traits, but no single “anxiety gene” exists — risk is polygenic and interacts strongly with environment [15].

7. What are the different types of anxiety disorders?

The DSM-5 recognizes several anxiety disorders [2]: generalized anxiety disorder (GAD) — chronic excessive worry across multiple domains; panic disorder — recurrent unexpected panic attacks plus persistent concern about future attacks; social anxiety disorder — intense fear of scrutiny or negative evaluation in social situations; specific phobias — marked fear of specific objects or situations (heights, animals, blood, flying); agoraphobia — fear of situations where escape might be difficult; and separation anxiety disorder.

8. What is the difference between stress and anxiety?

Stress is a response to an identifiable external demand or threat and typically resolves when the stressor is removed [17]. Anxiety persists even in the absence of a clear external trigger, is future-oriented, and often involves anticipatory worry about events that may never occur [1]. Acute stress can be adaptive and improve performance, while sustained stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis and increases risk for anxiety and depressive disorders [18].

9. Can anxiety cause physical symptoms?

Yes. Anxiety triggers sympathetic nervous system activation, producing chest tightness or pain, palpitations, shortness of breath, dizziness, nausea, diarrhea, muscle tension, headaches, sweating, trembling, and tingling in the extremities [19]. Chronic anxiety is also associated with increased risk of cardiovascular disease, irritable bowel syndrome, tension headaches, and immune dysregulation [20]. Because anxiety can mimic cardiac and respiratory conditions, new or severe physical symptoms should always be evaluated medically before being attributed to anxiety [7].

10. Why do I feel anxious for no reason?

“Anxiety from nowhere” usually has identifiable causes that are not consciously recognized: subclinical caffeine or stimulant effects, poor or fragmented sleep, blood sugar fluctuations, hormonal shifts (premenstrual, perimenopausal, thyroid), withdrawal from alcohol or sedatives, low-grade chronic stress, unresolved trauma, or genetic predisposition expressed as baseline hyperarousal [21]. Interoceptive sensitivity — heightened awareness of normal bodily sensations — can also be misinterpreted as threat, generating anxiety in the absence of an external trigger [22].

Anxiety — treatment, coping, and daily management

11. How do I stop a panic attack quickly?

Evidence-based techniques include slow diaphragmatic breathing (inhale 4 seconds, exhale 6–8 seconds) to activate the parasympathetic nervous system [23]; the 5-4-3-2-1 grounding exercise (name 5 things you see, 4 you feel, 3 you hear, 2 you smell, 1 you taste) to redirect attention from internal sensations [24]; cold-water exposure (splashing the face or holding a cold object) which triggers the mammalian dive reflex and slows heart rate [25]; and accepting the attack rather than fighting it — research shows resistance prolongs panic, while acceptance shortens it [26]. Reminding yourself that panic peaks within ~10 minutes and is not dangerous reduces secondary fear [7].

12. What are the best treatments for anxiety?

The two first-line evidence-based treatments are cognitive-behavioral therapy (CBT) — including exposure therapy for phobias, panic, and social anxiety — and SSRIs/SNRIs [27,28]. Meta-analyses show CBT produces large effect sizes (Cohen’s d ≈ 0.80) and gains are durable at long-term follow-up, often outperforming medication on relapse prevention [29]. SSRIs (escitalopram, sertraline, paroxetine) and SNRIs (venlafaxine, duloxetine) are first-line pharmacotherapy [28]. Combining CBT with medication is often more effective than either alone for moderate-to-severe cases [30].

13. Do anxiety medications work and what are the side effects?

Common side effects include nausea, sexual dysfunction, sleep changes, sweating, and weight change; most diminish within 2–4 weeks [32]. Benzodiazepines (lorazepam, clonazepam) work within 30 minutes for acute anxiety but carry significant risks of tolerance, dependence, and cognitive impairment, and are recommended only for short-term use (≤2–4 weeks) or specific situations [33]. Buspirone and pregabalin are non-addictive alternatives for generalized anxiety [34].

14. Can anxiety be cured or does it come back?

In relapse-prevention trials with up to one year of follow-up, about 36% of people relapsed after switching from an antidepressant to placebo versus about 16% who continued the antidepressant [154]. CBT is associated with lower relapse rates than medication, likely because skills learned in therapy persist beyond treatment [29].

15. How can I reduce anxiety naturally without medication?

Evidence-based non-pharmacological strategies include regular aerobic exercise (≥150 min/week — comparable to medication for mild-to-moderate anxiety) [37], mindfulness-based stress reduction (MBSR) [38], cognitive-behavioral self-help and digital CBT programs [39], yoga and structured breathing practices [40], adequate sleep (7–9 hours) [41], limiting caffeine and alcohol [42], and social connection [43]. These approaches are most effective when combined and are recommended as first-line for mild anxiety per international guidelines [27].

16. Does exercise help anxiety?

Yes — robustly. Meta-analyses of randomized trials show aerobic and resistance exercise produce moderate-to-large reductions in anxiety symptoms, with effect sizes (Cohen’s d ≈ 0.55–0.85) comparable to first-line medications and CBT for mild-to-moderate anxiety [37,44]. Mechanisms include reduced HPA-axis reactivity, increased GABA and serotonin availability, elevated BDNF (brain-derived neurotrophic factor), and improved sleep [45]. Even single sessions of 20–30 minutes of moderate-intensity exercise produce measurable acute anxiolytic effects [46].

17. How does caffeine, alcohol, or nicotine affect anxiety?

Caffeine antagonizes adenosine receptors and stimulates the sympathetic nervous system; doses ≥200 mg can induce panic attacks in susceptible individuals, and >400 mg/day increases generalized anxiety [42,47]. Alcohol initially reduces anxiety via GABA enhancement but causes rebound anxiety during withdrawal (often 6–24 hours after last drink); chronic use worsens anxiety disorders and reduces treatment response [48]. Nicotine produces brief calming via acetylcholine receptors but cumulative use elevates baseline anxiety; quitting is associated with significant long-term anxiety reduction [49].

18. How do breathing exercises and grounding techniques help anxiety?

Slow paced breathing (≤6 breaths per minute) increases vagal tone, activates the parasympathetic nervous system, raises heart rate variability, and reduces amygdala activation, producing measurable reductions in state anxiety within minutes [23,50]. Grounding techniques (5-4-3-2-1, body scan, naming objects) shift attention from internal threat-monitoring to external sensory input, interrupting catastrophic thinking and dampening interoceptive amplification [24,51]. Both techniques are evidence-based components of CBT and trauma-focused therapy [52].

Depression — what it is, symptoms, and causes

19. What is depression and how is it different from sadness?

Sadness is a normal, time-limited emotional response to loss or disappointment that does not significantly impair functioning. Major depressive disorder (MDD) is a clinical syndrome lasting at least two weeks with five or more of: depressed mood, loss of interest or pleasure (anhedonia), significant weight or appetite change, sleep disturbance, psychomotor agitation or slowing, fatigue, feelings of worthlessness or excessive guilt, impaired concentration, and recurrent thoughts of death or suicide [2,53]. Depression involves persistent biological and cognitive changes — including HPA-axis dysregulation, reduced hippocampal volume, and negatively biased information processing — that distinguish it from ordinary sadness [54].

20. What are the symptoms of clinical depression (MDD)?

DSM-5 requires ≥5 symptoms for ≥2 weeks, including at least one of depressed mood or anhedonia [2]: persistent low mood; loss of interest or pleasure; significant weight loss or gain (>5%) or appetite change; insomnia or hypersomnia; psychomotor agitation or retardation observable to others; fatigue or loss of energy; feelings of worthlessness or excessive guilt; impaired concentration or indecisiveness; and recurrent thoughts of death or suicide. Symptoms must cause significant distress or functional impairment and not be better explained by substance use or another medical condition [53].

21. What causes depression?

Depression has a multifactorial etiology: genetic (heritability ~37%) [55]; neurobiological — dysregulation of serotonin, norepinephrine, and dopamine systems; HPA-axis hyperactivity; neuroinflammation; reduced hippocampal and prefrontal volumes [54,56]; psychological — negative cognitive schemas, rumination, learned helplessness [57]; environmental — childhood adversity, trauma, chronic stress, loss, social isolation, financial strain [58]; and medical — hypothyroidism, vitamin D and B12 deficiency, certain medications, chronic illness, and substance use [59]. The most accepted framework is the biopsychosocial model.

22. Is depression genetic?

Partly. Twin studies estimate heritability of major depression at approximately 37% [55]. In a 20-year follow-up, children of depressed parents had about three times the risk of major depression, anxiety disorders and substance dependence compared with children of non-depressed parents [155]. However, no single “depression gene” exists — depression is highly polygenic, with hundreds of small-effect genetic variants identified by genome-wide association studies, and gene-environment interactions (especially with childhood adversity) are central to risk [15,61].

23. What is the difference between major depression, persistent depressive disorder, and seasonal affective disorder?

Major depressive disorder (MDD) — discrete episodes of ≥2 weeks of severe symptoms; episodes can be single or recurrent [2]. Persistent depressive disorder (dysthymia) — chronic, lower-intensity depressed mood lasting ≥2 years (≥1 year in youth) with at least two associated symptoms [2,62]. Seasonal affective disorder (SAD) — a specifier of recurrent MDD or bipolar disorder with episodes occurring in a seasonal pattern (typically fall/winter) and remitting in spring/summer; linked to reduced daylight and circadian disruption [63]. SAD responds well to bright-light therapy (10,000 lux for 30 minutes each morning) [64].

24. Can depression cause physical symptoms?

Yes. Common physical manifestations include persistent fatigue, unexplained aches and pains, headaches, gastrointestinal symptoms, sleep disturbance, appetite and weight changes, psychomotor slowing, and reduced libido [65]. In an international primary-care study, about half of depressed patients reported multiple unexplained somatic symptoms, and across study centres 45% to 95% reported with only somatic symptoms [156]. Depression also increases inflammation (elevated CRP, IL-6) and is associated with higher rates of cardiovascular disease, diabetes, and chronic pain syndromes [67].

25. What is high-functioning depression?

“High-functioning depression” is a colloquial term — not a formal diagnosis — usually corresponding to persistent depressive disorder (dysthymia) or atypical/mild MDD in individuals who maintain work, school, and relationships despite chronic depressive symptoms [62]. People with this presentation often experience persistent low mood, anhedonia, fatigue, low self-esteem, and rumination but are reluctant to seek help because they are “still functioning.” Untreated, it carries elevated risk of progression to major depressive episodes and suicidal ideation, and warrants the same evidence-based treatment as other forms of depression [69].

26. What is postpartum depression and how is it treated?

About 1 in 8 women who have recently given birth report symptoms of postpartum depression [157]. Symptoms include depressed mood, anhedonia, sleep disruption beyond newborn-related changes, intense guilt or feelings of inadequacy, anxiety, and impaired bonding. Evidence-based treatments include cognitive-behavioral therapy, interpersonal therapy, SSRIs (sertraline is first-line during breastfeeding), and brexanolone or zuranolone (FDA-approved neurosteroids for PPD) [72,73]. Untreated PPD adversely affects maternal, infant, and family outcomes; early identification and treatment are critical.

27. How do I know if I’m depressed or just sad?

Sadness is typically time-limited (hours to a few days), tied to a clear trigger, and does not impair core functioning. Depression involves persistent (≥2 weeks) low mood or loss of interest in nearly all activities, accompanied by changes in sleep, appetite, energy, concentration, self-worth, or thoughts of death [2]. Validated self-report tools such as the PHQ-9 (Patient Health Questionnaire-9) classify scores: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe; scores ≥10 warrant clinical evaluation [74]. If symptoms persist >2 weeks or include hopelessness or suicidal thoughts, professional assessment is recommended.

28. Why do I feel depressed for no reason?

Depression often appears without an obvious external trigger because risk factors are biological, cumulative, or operate outside conscious awareness: genetic predisposition; chronic low-grade stress; circadian and sleep disruption; vitamin D, B12, or iron deficiency; thyroid dysfunction; hormonal fluctuations (premenstrual, postpartum, perimenopausal); chronic inflammation; medication side effects (corticosteroids, beta-blockers, hormonal contraceptives); seasonal light reduction; and unresolved early-life adversity [55,58,59,75]. Endogenous depression — depression with no identifiable trigger — is recognized in clinical practice and responds to the same evidence-based treatments as reactive depression [76].

Depression — treatment and recovery

29. What are the most effective treatments for depression?

First-line evidence-based treatments are psychotherapy (CBT, behavioral activation, interpersonal therapy, problem-solving therapy) and antidepressants (SSRIs, SNRIs, atypicals such as bupropion and mirtazapine) [77,78]. In a network meta-analysis of 21 antidepressants, all were more effective than placebo for acute treatment of adult major depression [31]. Combined therapy plus medication outperforms either alone for moderate-to-severe depression [79]. For treatment-resistant depression, augmentation strategies, ketamine/esketamine, repetitive transcranial magnetic stimulation (rTMS), and electroconvulsive therapy (ECT) have strong evidence [80,81].

30. How long do antidepressants take to work and how long should you stay on them?

Most patients begin to feel partial improvement within 2–4 weeks, with full benefit typically at 6–12 weeks [82]. International guidelines recommend continuing antidepressants for at least 6–9 months after symptom remission for a first episode; for recurrent depression (≥2 episodes), maintenance treatment of 2 years or longer reduces relapse risk substantially [77,83]. Discontinuation should be gradual (typically over weeks to months) and supervised, as abrupt cessation can cause antidepressant discontinuation syndrome — flu-like symptoms, dizziness, sensory disturbances, mood symptoms — particularly with paroxetine and venlafaxine [84].

31. What are the side effects of antidepressants?

In a prospective study of 1,022 outpatients, sexual dysfunction occurred in 59% of people taking antidepressants overall, and in about 58% to 73% of those taking individual SSRIs or venlafaxine [158]. Less common but serious risks include serotonin syndrome (with serotonergic combinations), QT prolongation (citalopram >40 mg), bleeding (with NSAIDs/anticoagulants), hyponatremia (especially in older adults), and increased suicidal ideation in those under 25 during the first weeks of treatment [86]. Bupropion lowers seizure threshold and avoids sexual side effects; mirtazapine is sedating and increases appetite [78].

32. Does therapy work for depression?

Yes. CBT in particular demonstrates lower relapse rates than medication after treatment ends, likely because skills are retained [89]. Therapy plus medication outperforms either alone for moderate-severe depression [79]. Even brief interventions (6–8 sessions) and digital CBT programs produce clinically meaningful improvement in mild-to-moderate depression [90].

33. Can depression be cured or does it always come back?

In a long-term follow-up study, the risk of a further episode of major depression increased by 16% with each successive recurrence [159]. Maintenance therapy — continued medication, booster psychotherapy sessions, mindfulness-based cognitive therapy (MBCT), and lifestyle measures — substantially reduces relapse risk [92]. Identifying and addressing residual symptoms (especially sleep, anhedonia, and rumination) and ongoing stressors is key to long-term recovery [93].

34. What helps depression naturally?

Evidence-based non-pharmacological strategies include regular aerobic exercise (≥150 min/week — comparable to medication for mild-to-moderate depression) [94]; bright-light therapy for SAD and non-seasonal depression [64,95]; sleep regularization (consistent schedule, 7–9 hours, sleep-restriction therapy) [96]; Mediterranean-style diet and omega-3 supplementation in those with deficiency [97,98]; mindfulness-based cognitive therapy [92]; behavioral activation [99]; and social connection and reducing isolation [100]. These approaches are recommended in international guidelines as first-line for mild depression and as adjuncts for moderate-severe cases [77].

35. What treatments exist for treatment-resistant depression?

Treatment-resistant depression (TRD) — typically defined as failure of ≥2 adequate antidepressant trials — is treated with: augmentation with lithium, atypical antipsychotics (aripiprazole, quetiapine), or thyroid hormone [80]; ketamine/esketamine (FDA-approved esketamine nasal spray) which produces rapid (within hours) but transient antidepressant effects via NMDA receptor modulation [81]; repetitive transcranial magnetic stimulation (rTMS) — non-invasive, FDA-cleared, response rates ~30–60% [101]; electroconvulsive therapy (ECT) — most effective treatment for severe TRD with response rates 60–80% [102]; and emerging treatments including psilocybin-assisted therapy (in clinical trials) and deep brain stimulation [103].

Mood swings, bipolar disorder, and other mood conditions

36. What causes sudden mood swings?

Common causes of acute mood swings include sleep deprivation, blood sugar fluctuations, hormonal shifts (premenstrual, postpartum, perimenopause, thyroid disorders), substance use or withdrawal (alcohol, caffeine, cannabis, stimulants), medication side effects (corticosteroids, hormonal contraceptives, levothyroxine), chronic stress, and unrecognized mental health conditions including bipolar disorder, borderline personality disorder, ADHD, and premenstrual dysphoric disorder (PMDD) [104]. Frequent or severe mood swings — especially episodes lasting days with significant functional impact — warrant clinical assessment.

37. Are mood swings a sign of bipolar disorder?

Not usually. Most everyday mood swings reflect normal emotional reactivity, sleep, stress, or hormonal factors and resolve within hours [104]. Bipolar disorder involves discrete episodes of mania (≥7 days) or hypomania (≥4 days) characterized by elevated or irritable mood, decreased need for sleep, racing thoughts, increased goal-directed activity, grandiosity, and risky behavior — alternating with depressive episodes; brief intraday mood shifts (lasting minutes to hours) are not characteristic of bipolar disorder [2,106]. Rapid mood shifts within a single day are more typical of borderline personality disorder, PMDD, or ADHD-related emotional dysregulation [107].

38. What is the difference between bipolar I, bipolar II, and cyclothymia?

Bipolar I: at least one full manic episode (≥7 days, or any duration if hospitalization is required), often with depressive episodes [2]. Bipolar II: at least one hypomanic episode (≥4 days, less severe than mania, no marked impairment or psychosis) plus at least one major depressive episode; depressive episodes typically dominate the course [108]. Cyclothymia: chronic (≥2 years) fluctuating mood with hypomanic and depressive symptoms that don’t meet full criteria for hypomania or major depression [2]. In a U.S. national survey, lifetime prevalence was 1.0% for bipolar I, 1.1% for bipolar II and 2.4% for subthreshold bipolar disorder [160].

39. What is the difference between mood swings and a mood disorder?

Mood swings are transient emotional fluctuations that respond to context and resolve within hours; they are part of normal emotional life. A mood disorder (major depression, persistent depressive disorder, bipolar disorders, premenstrual dysphoric disorder, disruptive mood dysregulation disorder) involves persistent or recurrent disturbances of mood lasting days to weeks, accompanied by changes in sleep, energy, appetite, concentration, and self-worth, and causing significant distress or functional impairment [2,53]. Frequency, duration, intensity, and impairment distinguish disorders from normal mood variation [110].

40. Can hormones cause mood changes?

Yes. Over 90% of women report some premenstrual symptoms, and fewer than 5% of women of childbearing age have the more severe form, premenstrual dysphoric disorder (PMDD) [161]. Studies report “baby blues” in about 39% of new mothers overall (range 13.7% to 76% across cultural and geographic settings; Tosto et al., 2023), while about 1 in 8 women report symptoms of postpartum depression [162] [163]. Perimenopause is a window of vulnerability for developing both depressive symptoms and major depressive episodes [164]. Thyroid: hypothyroidism is associated with depression, hyperthyroidism with anxiety and mania [113]. Testosterone: low levels in men contribute to depression and fatigue [114]. Hormonal causes should be screened in any new-onset mood disorder.

41. How do sleep and diet affect mood?

Sleep and mood are bidirectionally linked: chronic sleep restriction (<6 hours) increases risk of depression by ~2-fold and worsens existing mood disorders, while improving sleep quality reliably improves mood [96,115]. Insomnia is both a risk factor for and a residual symptom of depression. In longitudinal studies, people with the highest adherence to a Mediterranean diet had about a 33% lower risk of developing depression than those with the lowest adherence [165]. Specific deficiencies of vitamin D, B12, folate, iron, and omega-3 fatty acids are linked to depressive symptoms and respond to repletion in deficient individuals [98,117].

42. Can vitamin deficiencies cause depression or mood changes?

Yes, in deficient individuals. Vitamin D: deficiency is associated with depression and supplementation modestly improves mood in those with low levels (<50 nmol/L) [117]. Vitamin B12 and folate: deficiencies impair monoamine synthesis and are linked to depression; supplementation helps in deficient patients [118]. Omega-3 (EPA/DHA): meta-analyses show modest antidepressant effects, particularly with EPA-predominant formulations [98]. Iron: deficiency causes fatigue and depressive symptoms, especially in women [119]. Routine supplementation in non-deficient individuals does not prevent or treat depression; testing and targeted repletion are recommended [120].

43. How is bipolar disorder treated?

Bipolar disorder requires lifelong management combining mood stabilizers (lithium — the gold standard, also reduces suicide risk; valproate; lamotrigine — particularly for bipolar depression; carbamazepine), atypical antipsychotics (quetiapine, olanzapine, lurasidone, aripiprazole), and structured psychotherapy (cognitive-behavioral therapy, family-focused therapy, interpersonal and social rhythm therapy) [121,122]. Antidepressant monotherapy is generally avoided in bipolar I due to risk of mania induction. Sleep regularization, mood charting, and substance-use management are essential. ECT is highly effective for severe or treatment-resistant episodes [102].

Co-occurring conditions, suicide safety, and when to seek help

44. Can you have anxiety and depression at the same time?

Yes — comorbidity is the norm, not the exception. Across the WHO World Mental Health Surveys, about 46% of people with lifetime major depression also had a lifetime anxiety disorder [166]. Comorbid anxiety-depression is associated with greater symptom severity, higher suicide risk, longer episodes, and poorer treatment response than either condition alone [125]. SSRIs and SNRIs are first-line for both, and CBT is effective for the combined presentation through transdiagnostic protocols such as the Unified Protocol [126].

45. What is the link between depression and suicide and what are the warning signs?

Lifetime suicide risk in affective disorders is about 2% in mixed inpatient/outpatient populations, about 4% among patients hospitalized for affective disorders, and 8.6% among those ever hospitalized for suicidality; the older 15% figure overstates the risk [167]. Warning signs: talking about wanting to die, hopelessness, feeling trapped or being a burden, increased substance use, withdrawal, dramatic mood changes, giving away possessions, researching means, and prior attempts (the strongest predictor) [129,130]. If you or someone you know is in crisis, call 911 immediately. Effective interventions include the Safety Planning Intervention, lithium for bipolar, clozapine for schizophrenia, and means restriction [131].

46. When should I see a doctor or therapist for anxiety or depression?

Seek professional evaluation if symptoms persist >2 weeks, interfere with work, school, relationships, or self-care, include hopelessness or suicidal thoughts, involve panic attacks, are accompanied by significant sleep, appetite, or weight changes, or worsen despite self-help [27,77]. Earlier intervention is associated with better outcomes and lower relapse risk. Free PHQ-9 (depression) and GAD-7 (anxiety) screening tools can guide whether to seek care: scores ≥10 on either suggest moderate symptoms warranting clinical assessment [74,132]. Crisis symptoms (suicidal ideation with plan or intent, severe agitation, psychosis) require immediate emergency evaluation.

47. What is the difference between a psychiatrist, psychologist, and therapist?

Psychiatrist: medical doctor (MD or DO) who can diagnose mental disorders and prescribe medication; some also provide psychotherapy [133]. Psychologist: doctoral-level (PhD or PsyD) clinician trained in psychological assessment and evidence-based psychotherapy; cannot prescribe medication in most jurisdictions (exceptions: New Mexico, Louisiana, Illinois, Iowa, Idaho, and a few others). For uncomplicated mild-moderate symptoms, any qualified evidence-based therapist is appropriate; complex, severe, or medication-requiring cases benefit from psychiatrist involvement and a multidisciplinary team.

48. Are anxiety and depression more common in teens, women, or older adults?

Meta-analyses of national samples show that women are about twice as likely as men to be diagnosed with major depression, a gap that emerges by about age 12 and peaks in adolescence [170]. Among U.S. adolescents aged 12 to 17, past-year major depressive episodes rose 52% from 2005 to 2017 (from 8.7% to 13.2%) [168]. Older adults: depression in late life is common but underdiagnosed, often presenting with cognitive complaints, somatic symptoms, and anhedonia rather than sadness [138]. Suicide rates are highest among older men, particularly those who are widowed, isolated, or chronically ill [139].

49. Can social media, screen time, or loneliness cause anxiety and depression?

Heavy social media use (>3 hours/day) is associated with increased risk of depression and anxiety in adolescents, with effect sizes that are small-to-moderate but consistent across studies; mechanisms include social comparison, sleep displacement, cyberbullying, and reduced in-person interaction [140,141]. Causality is debated and likely bidirectional, with vulnerable individuals more susceptible. Loneliness independently predicts depression, anxiety, and increased mortality, with effect sizes comparable to smoking [142,143]. Reducing problematic social media use, regular sleep, and structured social connection are evidence-based protective factors [144].

50. Does neurofeedback, mindfulness, or meditation help anxiety, depression, or mood?

An individual-patient meta-analysis found MBCT reduced the risk of depressive relapse over 60 weeks by about 31% compared with not receiving MBCT, and also compared favourably with active treatments (hazard ratio 0.79) [169]. Meditation: regular practice produces measurable changes in default-mode network activity, amygdala reactivity, and prefrontal regulation [147]. Neurofeedback (EEG biofeedback): meta-analyses support efficacy for ADHD, PTSD, and anxiety symptoms; evidence in major depression is growing, with frontal alpha asymmetry and infra-low frequency protocols showing benefit but requiring more high-quality RCTs [148,149,150]. These approaches are best used as adjuncts to evidence-based therapy and medication for moderate-severe disorders, and as primary interventions for mild presentations.

References

  1. Craske, M. G., & Stein, M. B. (2016). Anxiety. The Lancet, 388(10063), 3048–3059.
  2. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). APA Publishing.
  3. Dugas, M. J., & Robichaud, M. (2007). Cognitive-behavioral treatment for generalized anxiety disorder: From science to practice. Routledge.
  4. Barlow, D. H. (2002). Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic (2nd ed.). Guilford.
  5. Roy-Byrne, P. P., et al. (2006). Panic disorder. The Lancet, 368(9540), 1023–1032.
  6. Craske, M. G., et al. (2010). Panic disorder: A review of DSM-IV panic disorder. Depression and Anxiety, 27(2), 93–112.
  7. Howard, D. M., Adams, M. J., Clarke, T.-K., Hafferty, J. D., Gibson, J., Shirali, M., Coleman, J. R. I., Hagenaars, S. P., Ward, J., Wigmore, E. M., Alloza, C., Shen, X., Barbu, M. C., Xu, E. Y., Whalley, H. C., Marioni, R. E., Porteous, D. J., Davies, G., Deary, I. J., … McIntosh, A. M. (2019). Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 22(3), 343–352. https://doi.org/10.1038/s41593-018-0326-7
  8. McEwen, B. S. (2007). Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain. Physiological Reviews, 87(3), 873–904. https://doi.org/10.1152/physrev.00041.2006
  9. Lupien, S. J., et al. (2009). Effects of stress throughout the lifespan on brain, behaviour and cognition. Nature Reviews Neuroscience, 10(6), 434–445.
  10. Domschke, K., Stevens, S., Pfleiderer, B., & Gerlach, A. L. (2010). Interoceptive sensitivity in anxiety and anxiety disorders: An overview and integration of neurobiological findings. Clinical Psychology Review, 30(1), 1–11. https://doi.org/10.1016/j.cpr.2009.08.008
  11. Roest, A. M., et al. (2010). Anxiety and risk of incident coronary heart disease. Journal of the American College of Cardiology, 56(1), 38–46.
  12. Ohayon, M. M. (2002). Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews, 6(2), 97–111. https://doi.org/10.1053/smrv.2002.0186
  13. Paulus, M. P., & Stein, M. B. (2010). Interoception in anxiety and depression. Brain Structure and Function, 214(5–6), 451–463.
  14. Brown, R. P., & Gerbarg, P. L. (2005). Sudarshan Kriya Yogic Breathing in the Treatment of Stress, Anxiety, and Depression: Part I—Neurophysiologic Model. The Journal of Alternative and Complementary Medicine, 11(1), 189–201. https://doi.org/10.1089/acm.2005.11.189
  15. Najavits, L. M. (2002). Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. Guilford.
  16. Foster, G. E., & Sheel, A. W. (2005). The human diving response, its function, and its control. Scandinavian Journal of Medicine & Science in Sports, 15(1), 3–12.
  17. Eifert, G. H., & Heffner, M. (2003). The effects of acceptance versus control contexts on avoidance of panic-related symptoms. Journal of Behavior Therapy and Experimental Psychiatry, 34(3), 293–312.
  18. Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. International clinical psychopharmacology, 30(4), 183–92. https://doi.org/10.1097/YIC.0000000000000078
  19. Slee, A., et al. (2019). Pharmacological treatments for generalized anxiety disorder: A systematic review and network meta-analysis. The Lancet, 393(10173), 768–777.
  20. Carpenter, J. K., Andrews, L. A., Witcraft, S. M., Powers, M. B., Smits, J. A. J., & Hofmann, S. G. (2018). Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials. Depression and Anxiety, 35(6), 502–514. https://doi.org/10.1002/da.22728
  21. Cuijpers, P., et al. (2014). Adding psychotherapy to antidepressant medication in depression and anxiety disorders. World Psychiatry, 13(1), 56–67.
  22. Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/s0140-6736(17)32802-7
  23. Ferguson, J. M. (2001). SSRI Antidepressant Medications: Adverse Effects and Tolerability. Primary care companion to the Journal of clinical psychiatry, 3(1), 22–27. https://doi.org/10.4088/pcc.v03n0105
  24. Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction, 106(12), 2086–2109.
  25. Generoso, M. B., et al. (2017). Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis. International Clinical Psychopharmacology, 32(1), 49–55.
  1. Stubbs, B., et al. (2017). An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Research, 249, 102–108.
  2. Hofmann, S. G., et al. (2010). The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. Journal of Consulting and Clinical Psychology, 78(2), 169–183.
  3. Andrews, G., et al. (2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. Journal of Anxiety Disorders, 55, 70–78.
  4. Cramer, H., et al. (2018). Yoga for anxiety: A systematic review and meta-analysis of randomized controlled trials. Depression and Anxiety, 35(9), 830–843.
  5. Walker, M. P. (2009). The role of sleep in cognition and emotion. Annals of the New York Academy of Sciences, 1156(1), 168–197.
  6. Lara, D. R. (2010). Caffeine, mental health, and psychiatric disorders. Journal of Alzheimer’s Disease, 20(s1), S239–S248.
  7. Holt-Lunstad, J., et al. (2010). Social relationships and mortality risk: A meta-analytic review. PLoS Medicine, 7(7), e1000316.
  8. Gordon, B. R., et al. (2017). Association of efficacy of resistance exercise training with depressive symptoms: Meta-analysis. JAMA Psychiatry, 75(6), 566–576.
  9. Kandola, A., et al. (2019). Moving to beat anxiety: Epidemiology and therapeutic issues with physical activity for anxiety. Current Psychiatry Reports, 20(8), 63.
  10. Petruzzello, S. J., et al. (1991). A meta-analysis on the anxiety-reducing effects of acute and chronic exercise. Sports Medicine, 11(3), 143–182.
  11. Bruce, M. S., & Lader, M. (1989). Caffeine abstention in the management of anxiety disorders. Psychological Medicine, 19(1), 211–214.
  12. Boschloo, L., et al. (2012). Alcohol use disorders and the course of depressive and anxiety disorders. British Journal of Psychiatry, 200(6), 476–484.
  13. Taylor, G., et al. (2014). Change in mental health after smoking cessation: Systematic review and meta-analysis. BMJ, 348, g1151.
  14. Lehrer, P. M., & Gevirtz, R. (2014). Heart rate variability biofeedback: How and why does it work? Frontiers in Psychology, 5, 756.
  15. Linehan, M. M. (2015). DBT Skills Training Manual (2nd ed.). Guilford.
  16. Foa, E. B., et al. (2007). Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences, Therapist Guide. Oxford University Press.
  17. Otte, C., et al. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2, 16065.
  18. Pandya, M., et al. (2012). Where in the brain is depression? Current Psychiatry Reports, 14(6), 634–642.
  19. Sullivan, P. F., et al. (2000). Genetic epidemiology of major depression: Review and meta-analysis. American Journal of Psychiatry, 157(10), 1552–1562.
  20. Belmaker, R. H., & Agam, G. (2008). Major depressive disorder. New England Journal of Medicine, 358(1), 55–68.
  21. Beck, A. T., & Bredemeier, K. (2016). A unified model of depression: Integrating clinical, cognitive, biological, and evolutionary perspectives. Clinical Psychological Science, 4(4), 596–619.
  22. Hammen, C. (2005). Stress and depression. Annual Review of Clinical Psychology, 1, 293–319.
  23. Ng, C. W. M., et al. (2017). Depression in primary care: Assessing suicide risk. Singapore Medical Journal, 58(2), 72–77.
  24. Caspi, A., et al. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386–389.
  25. Schramm, E., Klein, D. N., Elsaesser, M., Furukawa, T. A., & Domschke, K. (2020). Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. The Lancet Psychiatry, 7(9), 801–812. https://doi.org/10.1016/s2215-0366(20)30099-7
  26. Rosenthal, N. E., et al. (1984). Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry, 41(1), 72–80.
  27. Golden, R. N., et al. (2005). The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis. American Journal of Psychiatry, 162(4), 656–662.
  28. Trivedi, M. H. (2004). The link between depression and physical symptoms. Primary Care Companion to the Journal of Clinical Psychiatry, 6(suppl 1), 12–16.
  29. Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22–34.
  30. Cuijpers, P., et al. (2010). Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clinical Psychology Review, 30(1), 51–62.
  1. Meltzer-Brody, S., et al. (2018). Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet, 392(10152), 1058–1070.
  2. Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., Kanes, S. J., & Lasser, R. (2021). Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA psychiatry, 78(9), 951–959. https://doi.org/10.1001/jamapsychiatry.2021.1559
  3. Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
  4. Patten, S. B., Williams, J. V., Lavorato, D. H., Modgill, G., Jetté, N., & Eliasziw, M. (2008). Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. General Hospital Psychiatry, 30(5), 407–413. https://doi.org/10.1016/j.genhosppsych.2008.05.001
  5. Parker, G. (2000). Classifying depression: Should paradigms lost be regained? American Journal of Psychiatry, 157(8), 1195–1203.
  6. Malhi, G. S., & Mann, J. J. (2018). Depression. The Lancet, 392(10161), 2299–2312.
  7. Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366.
  8. Cuijpers, P., et al. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92–107.
  9. Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., & Möller, H.-J. (2015). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015. The World Journal of Biological Psychiatry, 16(2), 76–95. https://doi.org/10.3109/15622975.2014.1001786
  10. McIntyre, R. S., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383–399.
  11. Posternak, M. A., & Zimmerman, M. (2005). Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry, 66(2), 148–158.
  12. Geddes, J. R., et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. The Lancet, 361(9358), 653–661.
  13. Fava, G. A., et al. (2015). Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychotherapy and Psychosomatics, 84(2), 72–81.
  14. Hammad, T. A., et al. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332–339.
  15. Hollon, S. D., et al. (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417–422.
  16. Karyotaki, E., et al. (2017). Efficacy of self-guided internet-based cognitive behavioral therapy in the treatment of depressive symptoms: A meta-analysis of individual participant data. JAMA Psychiatry, 74(4), 351–359.
  17. Kuyken, W., et al. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: An individual patient data meta-analysis from randomized trials. JAMA Psychiatry, 73(6), 565–574.
  18. Paykel, E. S. (2008). Partial remission, residual symptoms, and relapse in depression. Dialogues in Clinical Neuroscience, 10(4), 431–437.
  19. Schuch, F. B., et al. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51.
  20. Lam, R. W., et al. (2016). Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 73(1), 56–63.
  21. Riemann, D., et al. (2020). Sleep, insomnia, and depression. Neuropsychopharmacology, 45(1), 74–89.
  22. Lassale, C., et al. (2019). Healthy dietary indices and risk of depressive outcomes: A systematic review and meta-analysis of observational studies. Molecular Psychiatry, 24(7), 965–986.
  23. Liao, Y., et al. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry, 9(1), 190.
  24. Ekers, D., et al. (2014). Behavioural activation for depression: An update of meta-analysis of effectiveness and sub-group analysis. PLoS One, 9(6), e100100.
  25. Cacioppo, J. T., Hughes, M. E., Waite, L. J., Hawkley, L. C., & Thisted, R. A. (2006). Loneliness as a specific risk factor for depressive symptoms: Cross-sectional and longitudinal analyses. Psychology and Aging, 21(1), 140–151. https://doi.org/10.1037/0882-7974.21.1.140
  26. Brunoni, A. R., et al. (2017). Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. JAMA Psychiatry, 74(2), 143–152.
  27. UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. The Lancet, 361(9360), 799–808.
  28. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., Forbes, M., Haumann, H. M., Hellerstein, D. J., Hoppe, A. I., Husain, M. I., Jelen, L. A., Kamphuis, J., Kawasaki, J., Kelly, J. R., Key, R. E., Kishon, R., Knatz Peck, S., Knight, G., Koolen, M. H. B., Lean, M., Licht, R. W., Maples-Keller, J. L., Mars, J., Marwood, L., McElhiney, M. C., Miller, T. L., Mirow, A., Mistry, S., Mletzko-Crowe, T., Modlin, L. N., Nielsen, R. E., Nielson, E. M., Offerhaus, S. R., O’Keane, V., Páleníček, T., Printz, D., Rademaker, M. C., van Reemst, A., Reinholdt, F., Repantis, D., Rucker, J., Rudow, S., Ruffell, S., Rush, A. J., Schoevers, R. A., Seynaeve, M., Shao, S., Soares, J. C., Somers, M., Stansfield, S. C., Sterling, D., Strockis, A., Tsai, J., Visser, L., Wahba, M., Williams, S., Young, A. H., Ywema, P., Zisook, S., & Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443
  29. Ebner-Priemer, U. W., & Trull, T. J. (2009). Ecological momentary assessment of mood disorders and mood dysregulation. Psychological Assessment, 21(4), 463–475.
  30. Grande, I., et al. (2016). Bipolar disorder. The Lancet, 387(10027), 1561–1572.
  31. Renaud, S. M., & Zacchia, C. (2012). Toward a definition of affective instability. Harvard Review of Psychiatry, 20(6), 298–308.
  32. Vieta, E., & Suppes, T. (2008). Bipolar II disorder: Arguments for and against a distinct diagnostic entity. Bipolar Disorders, 10(1, pt 2), 163–178.
  33. Watson, D. (2005). Rethinking the mood and anxiety disorders: A quantitative hierarchical model for DSM-V. Journal of Abnormal Psychology, 114(4), 522–536.
  1. Bauer, M., et al. (2008). The thyroid–brain interaction in thyroid disorders and mood disorders. Journal of Neuroendocrinology, 20(10), 1101–1114.
  2. Zarrouf, F. A., et al. (2009). Testosterone and depression: Systematic review and meta-analysis. Journal of Psychiatric Practice, 15(4), 289–305.
  3. Baglioni, C., et al. (2011). Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders, 135(1–3), 10–19.
  4. Anglin, R. E. S., et al. (2013). Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. British Journal of Psychiatry, 202(2), 100–107.
  5. Coppen, A., & Bolander-Gouaille, C. (2005). Treatment of depression: Time to consider folic acid and vitamin B12. Journal of Psychopharmacology, 19(1), 59–65.
  6. Beard, J. L., et al. (2005). Maternal iron deficiency anemia affects postpartum emotions and cognition. Journal of Nutrition, 135(2), 267–272.
  7. Sarris, J., et al. (2016). Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. American Journal of Psychiatry, 173(6), 575–587.
  8. Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. The Lancet, 381(9878), 1672–1682.
  9. Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O’Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., McIntyre, R. S., Kozicky, J., Kanba, S., Lafer, B., Suppes, T., Calabrese, J. R., Vieta, E., Malhi, G., Post, R. M., & Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609
  10. Fava, M., et al. (2008). Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. American Journal of Psychiatry, 165(3), 342–351.
  11. Barlow, D. H., Farchione, T. J., Bullis, J. R., Gallagher, M. W., Murray-Latin, H., Sauer-Zavala, S., Bentley, K. H., Thompson-Hollands, J., Conklin, L. R., Boswell, J. F., Ametaj, A., Carl, J. R., Boettcher, H. T., & Cassiello-Robbins, C. (2017). The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Compared With Diagnosis-Specific Protocols for Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry, 74(9), 875. https://doi.org/10.1001/jamapsychiatry.2017.2164
  12. Franklin, J. C., et al. (2017). Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research. Psychological Bulletin, 143(2), 187–232.
  13. World Health Organization. (2014). Preventing suicide: A global imperative. World Health Organization.
  14. Stanley, B., & Brown, G. K. (2012). Safety planning intervention: A brief intervention to mitigate suicide risk. Cognitive and Behavioral Practice, 19(2), 256–264.
  15. Spitzer, R. L., et al. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097.
  16. American Psychiatric Association. (2026). What is Psychiatry? APA.
  17. Alexopoulos, G. S. (2005). Depression in the elderly. The Lancet, 365(9475), 1961–1970.
  18. Conwell, Y., et al. (2011). Suicide in older adults. Psychiatric Clinics of North America, 34(2), 451–468.
  19. Twenge, J. M., et al. (2018). Increases in depressive symptoms, suicide-related outcomes, and suicide rates among U.S. adolescents after 2010 and links to increased new media screen time. Clinical Psychological Science, 6(1), 3–17.
  20. Orben, A., & Przybylski, A. K. (2019). The association between adolescent well-being and digital technology use. Nature Human Behaviour, 3(2), 173–182.
  21. Cacioppo, J. T., & Cacioppo, S. (2018). The growing problem of loneliness. The Lancet, 391(10119), 426.
  22. Holt-Lunstad, J., et al. (2015). Loneliness and social isolation as risk factors for mortality: A meta-analytic review. Perspectives on Psychological Science, 10(2), 227–237.
  23. Hunt, M. G., et al. (2018). No more FOMO: Limiting social media decreases loneliness and depression. Journal of Social and Clinical Psychology, 37(10), 751–768.
  24. Tang, Y.-Y., Hölzel, B. K., & Posner, M. I. (2015). The neuroscience of mindfulness meditation. Nature Reviews Neuroscience, 16(4), 213–225. https://doi.org/10.1038/nrn3916
  25. Arns, M., et al. (2014). Evaluation of neurofeedback in ADHD: The long and winding road. Biological Psychology, 95, 108–115.
  26. van der Kolk, B. A., et al. (2016). A randomized controlled study of neurofeedback for chronic PTSD. PLoS One, 11(12), e0166752.
  27. Micoulaud-Franchi, J. A., et al. (2021). EEG neurofeedback for anxiety disorders and post-traumatic stress disorders: A blueprint for a promising brain-based therapy. Current Psychiatry Reports, 23(12), 84.
  28. Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience, 17(3), 327–335. https://doi.org/10.31887/DCNS.2015.17.3/bbandelow
  29. Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K., & Walters, E. E. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry, 63(4), 415. https://doi.org/10.1001/archpsyc.63.4.415
  30. Hettema, J. M., Neale, M. C., & Kendler, K. S. (2001). A review and meta-analysis of the genetic epidemiology of anxiety disorders. American Journal of Psychiatry, 158(10), 1568–1578. https://doi.org/10.1176/appi.ajp.158.10.1568
  31. Batelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M., & van Balkom, A. J. L. M. (2017). Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ, 358, j3927. https://doi.org/10.1136/bmj.j3927
  32. Weissman, M. M., Wickramaratne, P., Nomura, Y., Warner, V., Pilowsky, D., & Verdeli, H. (2006). Offspring of depressed parents: 20 years later. American Journal of Psychiatry, 163(6), 1001. https://doi.org/10.1176/appi.ajp.163.6.1001
  33. Simon, G. E., VonKorff, M., Piccinelli, M., Fullerton, C., & Ormel, J. (1999). An international study of the relation between somatic symptoms and depression. New England Journal of Medicine, 341(18), 1329–1335. https://doi.org/10.1056/NEJM199910283411801
  34. Centers for Disease Control and Prevention. (2023, November 28). Symptoms of depression among women. https://www.cdc.gov/reproductive-health/depression/index.html
  35. Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico-Villademoros, F. (2001). Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry, 62(Suppl 3), 10–21. https://pubmed.ncbi.nlm.nih.gov/11229449/
  36. Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., & Endicott, J. (2000). Multiple recurrences of major depressive disorder. American Journal of Psychiatry, 157(2), 229–233. https://doi.org/10.1176/appi.ajp.157.2.229
  37. Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., et al. (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry, 64(5), 543. https://doi.org/10.1001/archpsyc.64.5.543
  38. Office on Women’s Health, U.S. Department of Health and Human Services. (2025, September 26). Premenstrual syndrome (PMS). https://www.womenshealth.gov/menstrual-cycle/premenstrual-syndrome
  39. Tosto, V., Ceccobelli, M., Lucarini, E., Tortorella, A., Gerli, S., Parazzini, F., & Favilli, A. (2023). Maternity blues: a narrative review. Journal of Personalized Medicine, 13(1), 154. https://doi.org/10.3390/jpm13010154
  40. Centers for Disease Control and Prevention. (2023, November 28). Symptoms of depression among women. https://www.cdc.gov/reproductive-health/depression/index.html
  41. Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., et al. (2018). Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause, 25(10), 1069–1085. https://doi.org/10.1097/GME.0000000000001174
  42. Lassale, C., Batty, G. D., Baghdadli, A., Jacka, F., Sánchez-Villegas, A., Kivimäki, M., et al. (2019). Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Molecular Psychiatry, 24(7), 965–986. https://doi.org/10.1038/s41380-018-0237-8
  43. Kessler, R. C., Sampson, N. A., Berglund, P., Gruber, M. J., Al-Hamzawi, A., Andrade, L., et al. (2015). Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiology and Psychiatric Sciences, 24(3), 210–226. https://doi.org/10.1017/S2045796015000189
  44. Bostwick, J. M., & Pankratz, V. S. (2000). Affective disorders and suicide risk: a reexamination. American Journal of Psychiatry, 157(12), 1925–1932. https://doi.org/10.1176/appi.ajp.157.12.1925
  45. Twenge, J. M., Cooper, A. B., Joiner, T. E., Duffy, M. E., & Binau, S. G. (2019). Age, period, and cohort trends in mood disorder indicators and suicide-related outcomes in a nationally representative dataset, 2005–2017. Journal of Abnormal Psychology, 128(3), 185–199. https://doi.org/10.1037/abn0000410
  46. Kuyken, W., Warren, F. C., Taylor, R. S., Whalley, B., Crane, C., Bondolfi, G., et al. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse. JAMA Psychiatry, 73(6), 565. https://doi.org/10.1001/jamapsychiatry.2016.0076
  47. Salk, R. H., Hyde, J. S., & Abramson, L. Y. (2017). Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychological Bulletin 143(8), 783-822. https://doi.org/10.1037/bul0000102

Need personalized support?

Dr. Samuel offers evidence-based counselling, therapy, and neurofeedback for anxiety, depression, mood, and trauma — with a 20-minute free intro call. Book a free 20-minute intro call →

Ready to talk? Your first 20 minutes are free. Call or text any day between 9am and 9pm — I respond within a couple of hours.

6047210604

[email protected]

25+
years clinical
Doctorate
LMCC · FSMB verified
2
languages — EN · فارسی
3
countries · frontline trauma
Therapy+
neurofeedback, one practice

Who you’re talking to

I’m Samuel Ezzatilord, PhD, RCC, CCC, LMCC. Over 25 years I’ve worked with trauma, anxiety, and relationships — from Red Crescent refugee camps and veterans’ clinics to community mental health here in Vancouver. I won’t be shocked by what you bring me, and I won’t rush you.

As an Iranian-Canadian clinician working in both English and Farsi, I understand the weight of آبرو, the pull between cultures, and how hard it can be to say “I need help” out loud. We go at your pace, find what’s really driving things, and work through it together.

My full story →

And no — your problem doesn’t need to be a crisis to belong here.

What happens when you call?

1
You call or text.

Dr. Samuel answers personally. No secretary, no forms, no gatekeeping.

2
You talk — 20 minutes, free.

Ask anything: fees, insurance, whether this approach fits you. Confidential within the limits of BC law and professional ethics.

3
You decide.

Book a first session — or don’t. Either way you leave with clarity and zero obligation.

Fees may be covered, depending on eligibility, by ICBC, CVAP, FNHA, IFHP, RCMP, VAC, and most other insurers, and direct billing is available.

سلب مسئولیت: محتوای این صفحه صرفاً جنبهٔ آشنایی عمومی دارد و جایگزین مشاوره، تشخیص یا درمان حرفه‌ای نیست. برای هرگونه تصمیم مربوط به سلامت روان، با یک متخصص واجد صلاحیت مشورت کنید.

Disclaimer: This page is for general-interest purposes only and does not constitute professional advice, diagnosis, or treatment. Consult a qualified professional for any mental-health decisions.

نوشته شده با همکاری تحریریه تخصصی · Written with expert editorial assistance

Notice: For general interest only; may contain inaccuracies. Not a diagnosis, treatment, prognosis, or professional, clinical, or legal advice. Reading this creates no counsellor-client relationship. By reading this page, you agree to these terms. Full disclaimer. In an emergency, call 911.

This page provides general information only and is not medical, psychological or legal advice.

این صفحه صرفاً اطلاعات عمومی ارائه می‌دهد و توصیه پزشکی، روان‌شناختی یا حقوقی نیست.

Dr SamuelCounselling · Therapy · Neurofeedback Certified Trauma Professional (CTP) — Evergreen CertificationsCertified Youth Mental Health Specialist (CYMHS) — Evergreen CertificationsCertified in Dialectical Behavior Therapy (C-DBT) — Evergreen Certifications
Call Now — FreeDirect line · No formsتماس مستقیم با ساموئل بدون دخالت منشی WhatsApp / Textواتساپ / پیامک Request a Callbackدرخواست تماس کتبی

Suite 1300, 1500 West Georgia Street, Vancouver, BC

6047210604

[email protected]

AFFILIATED WITH
BCACC
RCC
BCACC RCC
CCPA
CCC
CCPA CCC
✚
Red Cross (IFRC)
⛰
Hollyburn Support
☀
Sun Life Lumino
SHIFA
Shifa Therapy
FNHA
FNHA Provider
Scroll to Top